MYOCD

Across TCGA pan-cancer cohorts, MYOCD RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of MYOCD’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MYOCD RNA is repressed in tumor relative to normal tissue. In most cancer types MYOCD is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and KICH are the cancer types where MYOCD tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MYOCD RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	−5.098	<.001	11	view →
COAD	Male	II,III,IV	−2.108	<.001	11	view →
KICH	Male	II,III,IV	−0.993	<.001	11	view →
LUAD	Female	III,IV	−1.435	<.001	10	view →
LUSC	Female	II,III,IV	−1.912	<.001	9	view →
KIRP	Male	All	−0.716	<.001	7	view →
UCEC	All	III,IV	−4.005	<.001	6	view →
BRCA	All	All	−0.798	<.001	6	view →
STAD	Female	All	−2.621	<.001	5	view →
READ	All	All	−2.787	<.001	3	view →
PRAD	All	All	−1.222	<.001	2	view →
THCA	Female	All	−0.237	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

MYOCD–BLCA

Open the BLCA breakdown →